The double-blinded randomized placebo control, phase III BOLERO-2 study, demonstrated that everolimus plus exemestane improved progression free survival (PFS) compared with exemestane alone in HR+ HER2- advanced BC that recurred or progressed during/after nonsteroidal aromatase inhibitors [3]. This evidence concerns the gene ERBB2 and breast cancer.